Skip to main content

Table 3 Comparison of pharmacokinetic parameters between 150 mg rifabutin and 300 mg rifabutin combined with lopinavir/ritonavir (200/50 mg)

From: Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients

 150 mg RBT EOD with LPV/r (400 mg/100 mg)
(n = 9)
300 mg RBT EOD with LPV/r (400 mg/100 mg)
(n = 7)
pvalue
(Median + IQR)(Median + IQR)
Rifabutin (RBT)
 Ctrough (ng/mL)53 (46–78)177 (94–266)0.044
 Cmax (ng/mL)296 (205–450)600 (403–717)0.313
 Tmax (h)3 (2–6)4 (2–4)0.657
 AUC0–12 h2528 (1684–2735)4042.5 (3469–5761)0.044
Clearance
 CL (L/h)51.5 (34.1–53.0)23.2 (20.1–24.9)0.044
 CL (L/h/kg)0.92 (0.63–1.02)0.84 (0.78–1.00)1.000
25-O-desacetyl-rifabutin (d-RBT)
 Ctrough (ng/mL)61 (39–65)103 (79–126)0.044
 Cmax (ng/mL)129 (111–157)160 (136–345)0.313
 Tmax (h)6 (2–8)3 (3–4)0.242
 AUC0–12 h (ng.h/mL)1200.5 (737.5–1295.5)1534 (1059.5–2351)1.000
  1. Data are presented as medians with the range in parentheses
  2. RBT rifabutin, d-RBT 25-O-desacetyl-rifabutin, EOD every other day (every 48 h), LPV/r lopinavir/ritonavir, CTn plasma drug concentration at a specified time, IQR interquartile range, Cmax maximum (peak) plasma drug concentration, Tmax Time to reach maximum (peak) plasma concentration following drug administration, C0 trough plasma concentration (measured concentration at the end of a dosing interval at steady state (48 h) [taken directly before next administration]), AUCt0–12h area under the plasma concentration-time curve within time span t0 to t2